Related Experiment Video
Updated: Jul 4, 2025

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
Amyloid-β-Induced Dendritic Spine Elimination Requires Ca2+-Permeable AMPA Receptors, AKAP-Calcineurin-NFAT
Tyler P Martinez1,2,3, Matthew E Larsen2,4, Emily Sullivan2
1Pharmacology PhD Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045.
Abstract:
Alzheimer's disease (AD) is associated with brain accumulation of synaptotoxic amyloid-β (Aβ) peptides produced by the proteolytic processing of amyloid precursor protein (APP). Cognitive impairments associated with AD correlate with dendritic spine and excitatory synapse loss, particularly within the hippocampus. In rodents, soluble Aβ oligomers (Aβo) impair hippocampus-dependent learning and memory, promote dendritic spine loss, inhibit NMDA-type glutamate receptor (NMDAR)-dependent long-term potentiation (LTP), and promote synaptic depression (LTD), at least in part through activation of the Ca2+-CaM-dependent phosphatase calcineurin (CaN). Yet, questions remain regarding Aβ-dependent postsynaptic CaN signaling specifically at the synapse to mediate its synaptotoxicity. Here, we use pharmacologic and genetic approaches to demonstrate a role for postsynaptic signaling via A kinase-anchoring protein 150 (AKAP150)-scaffolded CaN in mediating Aβ-induced dendritic spine loss in hippocampal neurons from rats and mice of both sexes. In particular, we found that Ca2+-permeable AMPA-type glutamate receptors (CP-AMPARs), which were previously shown to signal through AKAP-anchored CaN to promote both LTD and Aβ-dependent inhibition of LTP, are also required upstream of AKAP-CaN signaling to mediate spine loss via overexpression of APP containing multiple mutations linked to familial early-onset AD (FAD) and increased Aβ production. In addition, we found that the CaN-dependent nuclear factor of activated T-cells (NFAT) transcription factors is required downstream to promote Aβ-mediated dendritic spine loss. Finally, we identified the E3-ubiquitin ligase Mdm2, which was previously linked to LTD and developmental synapse elimination, as a downstream NFAT target gene upregulated by Aβ whose enzymatic activity is required for Aβ-mediated spine loss.
Insights
Alzheimer's disease (AD) involves amyloid-beta (Aβ) causing synapse loss. This study reveals a pathway where Aβ triggers Mdm2, an E3-ubiquitin ligase, leading to dendritic spine loss in the hippocampus.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) accumulation and synaptic dysfunction.
- Soluble Aβ oligomers impair learning, memory, and synaptic plasticity in the hippocampus.
- Calcineurin (CaN) signaling is broadly implicated in Aβ-induced synaptotoxicity, but synapse-specific mechanisms remain unclear.
Purpose of the Study:
- To elucidate the specific postsynaptic signaling pathway by which Aβ induces dendritic spine loss in hippocampal neurons.
- To identify key molecular players involved in Aβ-mediated synaptotoxicity at the synapse.
Main Methods:
- Pharmacologic and genetic approaches in rat and mouse hippocampal neurons.
- Investigation of signaling pathways involving A kinase-anchoring protein 150 (AKAP150), calcineurin (CaN), and nuclear factor of activated T-cells (NFAT).
- Analysis of the role of Ca2+-permeable AMPA receptors (CP-AMPARs) and the E3-ubiquitin ligase Mdm2 in Aβ-induced spine loss.
Main Results:
- Aβ-induced dendritic spine loss requires postsynaptic AKAP150-scaffolded CaN signaling.
- Ca2+-permeable AMPA receptors (CP-AMPARs) are essential upstream mediators of this AKAP-CaN pathway.
- CaN-dependent NFAT transcription factors are required downstream, leading to the upregulation of the E3-ubiquitin ligase Mdm2.
- Mdm2 enzymatic activity is necessary for Aβ-mediated dendritic spine loss.
Conclusions:
- Aβ triggers a synapse-to-nucleus signaling cascade involving AKAP150, CaN, and NFAT.
- This pathway culminates in the transcriptional upregulation of Mdm2, which mediates Aβ-induced spine loss.
- Mdm2 represents a potential therapeutic target for mitigating synaptic damage in Alzheimer's disease.

